Last reviewed · How we verify
Other Therapeutic Agents
At a glance
| Generic name | Other Therapeutic Agents |
|---|---|
| Sponsor | BeiGene |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- Examining Analgesic Synergy and Efficacy in Trauma Care (PHASE4)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma (PHASE2)
- Feasibility of A Smartphone Application Intervention in Community Settings: A Pretest-Posttest Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other Therapeutic Agents CI brief — competitive landscape report
- Other Therapeutic Agents updates RSS · CI watch RSS
- BeiGene portfolio CI